Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Formation of the nephric duct
  • CDH11 homotypic and heterotypic interactions
  • Specification of the neural plate border
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Urea
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Gastric cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Colorectal cancer
  • Endometrial Cancer
CTTN cortactin
  • RHO GTPases activate PAKs
  • Clathrin-mediated endocytosis
DAPK3 death associated protein kinase 3
  • Caspase activation via Dependence Receptors in the absence of ligand
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid
  • (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
  • Fostamatinib
DCN decorin
  • Degradation of the extracellular matrix
  • Glycosaminoglycan-protein linkage region biosynthesis
  • CS-GAG biosynthesis
  • DS-GAG biosynthesis
  • CS/DS degradation
  • ECM proteoglycans
  • ECM proteoglycans
  • Defective B4GALT7 causes EDS, progeroid type
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective CHSY1 causes TPBS
  • Defective B3GALT6 causes EDSP2 and SEMDJL1
  • Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy
DNAJA3 DnaJ heat shock protein family (Hsp40) member A3
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
EPHA2 EPH receptor A2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
  • Fostamatinib
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Breast cancer
  • Cervical cancer
  • Cholangiocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Ovarian cancer
  • Choriocarcinoma
  • Endometrial Cancer
  • Bladder cancer
FAS Fas cell surface death receptor
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Esophageal cancer
  • Chronic lymphocytic leukemia (CLL)
  • Hodgkin lymphoma
  • Adult T-cell leukemia
FES FES proto-oncogene, tyrosine kinase
  • Signaling by SCF-KIT
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Fostamatinib
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Infigratinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FOXA3 forkhead box A3
  • Regulation of gene expression in beta cells
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
GLMN glomulin, FKBP associated protein
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Venous malformations, including: Sporadic venous malformation; Cutaneomucosal venous malformation; Glomuvenous malformation
GRB14 growth factor receptor bound protein 14
  • Tie2 Signaling
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
GRB7 growth factor receptor bound protein 7
  • GRB7 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signal transduction
  • Tie2 Signaling
  • RET signaling
  • RND1 GTPase cycle

Page 8 out of 13 pages